Figure 1. Effect of CSF1R inhibitor on tumor infiltration by PMN-MDSC.

A. Effect of JNJ-40346527 treatment on tumor growth in different tumor models. JNJ-40346527 was administered 6 days a week orally (20 mg/kg) from one day after tumor inoculation and continued until end of observation. Tumors size in mm² is shown. Each group included 5–9 mice. Means and SD are shown. B–D. The proportion of cells in tumors from mice at the end of the treatment as described in Fig. 1A. Each group included 5–8 mice. Means and SD are shown. * - p<0.05, **- p<0.01, *** - p<0.001 in Student’s t-test from vehicle control group. B. CD11b⁺Gr-1⁻F4/80^hi TAM. C. CD11b⁺Ly6C^hiLy6G⁻ monocytic cells. D. CD11b⁺Ly6C^loLy6G⁺ granulocytic cells. E. Immune suppressive activity of Ly6G⁺ cells isolated from tumors of JNJ-40346527 treated mice. Ly6G⁺ cells were added at indicated ratios to splenocytes from Pmel transgenic mice and stimulated with cognate peptide. Proliferation was measured by ³H-thymidine incorporation in triplicates. Two experiments with the same results were performed. **- p<0.01, *** - p<0.001 in Student’s t-test from splenocytes alone. F. The absolute number of myeloid cells per gram tumor of JNJ-40346527 treated mice in indicated tumor models. See also Figures S1.